July 7, 2016 09:08 AM EDTUpdated June 28, 12:29 PM

Master dealmaker? Medivation CEO David Hung’s overzealous PARP assault falls flat

Medivation doesn’t look any further ahead now that the CEO is publicly defending the asset like a dog defends a bone

Back when …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE LOG IN

TRENDING NOW

Lilly shuffles key executive positions; Mikael Dolsten takes another post-Pfizer assignment

Corvus' early-phase atopic dermatitis data prompt stock rally

AI biotech Insilico Medicine goes for third attempt at Hong Kong IPO

'Find a way, or make one': How two scientists hope to revitalize CRISPR's rare disease crisis

GSK awaits Nucala decision after FDA target date passes

sponsored

In one of the riskiest industries — Biotech — a surefire way to neutralize some of that risk emerges